Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.
Pharma & Biotech